Gelteq Limited (GELS)
NASDAQ: GELS · Real-Time Price · USD
2.590
-0.130 (-4.78%)
Dec 20, 2024, 4:00 PM EST - Market closed
Company Description
Gelteq Limited focuses on developing, testing, and commercializing white label gel-based delivery solutions for humans and animals.
It offers edible gels for prescription drugs, nutraceuticals, pet care, and other products, as well as for sports and over-the-counter products.
Gelteq Limited was incorporated in 2017 and is headquartered in Caulfield, Australia.
Gelteq Limited
Country | Australia |
Founded | 2018 |
IPO Date | Oct 29, 2024 |
Industry | Drug Manufacturers - Specialty & Generic |
Sector | Healthcare |
Employees | 8 |
CEO | Nathan Givoni |
Contact Details
Address: 639-641 Glenhuntly Road Caulfield, VIC 3162 Australia | |
Phone | 61 3 9087 3990 |
Website | gelteq.com |
Stock Details
Ticker Symbol | GELS |
Exchange | NASDAQ |
Fiscal Year | July - June |
Reporting Currency | AUD |
IPO Price | $4.00 |
CIK Code | 0001920092 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Nathan Jacob Givoni | Co-Founder, Chief Executive Officer and Director |
Simon Hayden Szewach | Co-Founder and Executive Chairman |
Anthony W. Panther A.C.I.S., AGIA, B.E., C.A., L.L.B., LL.B | Chief Financial Officer |
Craig J. Young | Chief Financial Officer and Company Secretary |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Nov 15, 2024 | 20-F | Annual and transition report of foreign private issuers |
Oct 31, 2024 | NT 20-F | Notification of inability to timely file Form 20-F |
Oct 30, 2024 | 6-K | Report of foreign issuer |
Oct 28, 2024 | CERT | Certification by an exchange approving securities for listing |
Oct 22, 2024 | 424B4 | Prospectus |
Oct 17, 2024 | 8-A12B | Registration of securities |
Sep 30, 2024 | EFFECT | Notice of Effectiveness |
Sep 25, 2024 | F-1/A | [Amend] Registration statement for certain foreign private issuers |
Sep 20, 2024 | UPLOAD | Filing |
Sep 12, 2024 | F-1/A | [Amend] Registration statement for certain foreign private issuers |